One would hope management would address the issues than let the...

One would hope management would address the issues than let the company fail of be taken over on the cheap.
Should get more guidance next Tuesday at HY results.

GP shortage is rapidly being addressed

The post-pandemic story is similar with diagnostic imaging provider Integral Diagnostics Ltd (ASX: IDX), with the stock losing more than half its value since April 2022.

The problem for both businesses, according to QV Equities portfolio manager Marc Whittaker, is that there is "a bottleneck when it comes to GP visitation".

"Whether that's because people are still loathe to get back to the GP after the COVID experience and/or the fact there's a bit of a shortage in GPs at the moment.

"We've had a controlled immigration intake for quite some time, and that really means a lot of GPs we rely on [who] come from offshore haven't been arriving."

But that inflow of foreign doctors is starting to now recover, and will be a tailwind for Integral Diagnostics.

"Top line's doing okay, costs just need to start normalising a little bit," said Whittaker.

"That top line should be enhanced by these GP visitations as they improve over time."